News Summary Peking University: PILOT LNPs reported to steer mRNA and genome editing tools to specific organs, expanding therapeutic targeting options. Pfizer/BioNTech: Topline Phase 3 data show robust immune response with LP.8.1-adapted COMIRNATY 2025–2026 formula. Cayman Chemical & Curapath: Partner to expand access to PEG-free shielding lipids for next-generation LNP formulations. PNAS/Northwestern: DNA-coated CRISPR LNP–spherical nucleic acids boost cellular uptake an